1. Torre LA, Siegel RL, Islami F, Bray F, Jemal A (2018). Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol 16.3: 427-437.
2. Jarnagin WR, Ruo L, Little SA, et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689-1700.
3. Valle J, Wasan H, Palmer DH, et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281
4. Lamarca A, Palmer DH, Wasan HS et al (2021). Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22.5: 690-701.
5. Paule B, Herelle MO, Rage E et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105-10
6. Suzuki E, Ikeda M, Okusaka T, et al (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71:1141-6
7. Bridgewater J, Palmer D, Cunningham D, et al (2013) Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 49:1511
8. Croitoru A, Gramaticu I, Dinu I, et al (2012) Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study. J Gastrointestin Liver Dis 21:277-84
9. Fornaro L, Vivaldi C, Cereda S, et al (2015) Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res 34:156
10. Sasaki T, Isayama H, Nakai Y, et al (2013) A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res 33:2619-22
11. Belov AA, Mohammadi M (2013) Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol 5
12. Churi CR, Shroff R, Wang Y, et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383
13. Javle M, Bekaii-Saab T, Jain A, et al (2016) Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer 122:3838-3847
14. Borad MJ, Champion MD, Egan JB, et al (2014) Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10:e1004135
15. Ross JS, Wang K, Gay L, et al (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19:235-42
16. Sia D, Losic B, Moeini A, et al (2015) Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 6:6087
17. Arai Y, Totoki Y, Hosoda F, et al (2014) Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59:1427-34
18. Wu YM, Su F, Kalyana-Sundaram S, et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3:636-47
19. Graham RP, Barr Fritcher EG, Pestova E, et al (2014) Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 45:1630-8
20. Kouhara H, Hadari YR, Spivak-Kroizman T, et al (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89:693-702
21. Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol, 21(5):671-684
22. Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36.3: 276
23. Bridgewater J, Meric-Bernstam F, Hollebecque A et al (2020) Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2). Ann Oncol 31: S261-S262.
24. Gozgit JM, Wong MJ, Moran L, et al (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11:690-9
25. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47
26. Oken MM, Creech RH, Tormey DC, et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-55
27. Common Terminology Criteria for Adverse Events (CTCAE) (2021). In: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed on July 2021
28. Kaupp-Roberts SD, Yadegarfar G, Friend E, et al (2016) Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. Br J Cancer 115:1032-1038
29. Friend E, Yadegarfar G, Byrne C, et al (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104:587-92
30. Chren MM, Lasek RJ, Sahay AP, Sands LP (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cut Med Surg 5.2: 105-110.
31. Atherton, PJ, Halyard MY, Sloan MJ et al (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA." Supp Care Cancer 21.4: 1193-1199.
32. Arora M, Bogenberger JM, Abdelrahman A et al (2020) Evaluation of NUC-1031: A first-in-class ProTide in biliary tract cancer." Cancer chemother pharmacol 85: 1063-1078.
33. Uson Junior PLS, Bogenberger J, Borad MJ (2020). "Advances in the treatment of biliary tract cancers." Curr opinion gastroenterol 36.2: 85-89.
34. Cleary JM, Iyer G, Oh DH et al (2020) Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. J Clin Oncol : 3603-3603
35. Valle JW, Bibeau K, Cho Y, et al (2021) Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib. J Clin Oncol 39:276-276
36. Bekaii-Saab TS, Valle JW, Van Cutsem E et al (2020) FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. J Clin Oncol, 38: abstr TPS592.
37. Javle MM, Borbath I, Clarke SJ et al (2019) Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. J Clin Oncol 37.15 suppl.
38. Goyal L, Saha SK, Liu LY, et al (2017) Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov 7:252-263
39. Goyal L, Shi L, Liu LY et al (2019) TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 Fusion–Positive intrahepatic cholangiocarcinoma. Cancer Disc; 9(8): 1064-1079.